| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.33 | -0.01 (-2.94%) | 0.255 - 0.51 | 120.7 thousand (Above Avg) |
Market data as of 10:10AM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 0.35 |
|---|---|
| Previous Close | 0.34 |
| Day's Range | 0.33 - 0.35 |
| Market Cap | 43.5M |
| Avg Volume (10 Day) | 169.2K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.23 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Fail |
InSite Vision Initiates Confirmatory Phase 3 Clinical Study of BromSite⢠for the Reduction of Inflammation and Pain after Cataract Surgery
Business Wire - Thursday 05/09/2013 5:00 PM ET
InSite Vision Reports First Quarter 2013 Financial Results
Business Wire - Tuesday 05/07/2013 4:00 PM ET
InSite Vision to Present Five Scientific Posters at 2013 ARVO Meeting
Business Wire - Monday 04/29/2013 8:32 AM ET
InSite Vision to Report First Quarter 2013 Financial Results on May 7, 2013
Business Wire - Monday 04/29/2013 8:30 AM ET
| INSV | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 2.21 |
| Company | Last | Change |
|---|---|---|
| Intellipharmaceutics International Inc | 1.79 | -2.72% |
| Delcath Systems Inc | 0.41 | -1.82% |
| Columbia Laboratories Inc | 0.62 | -0.24% |
| pSivida Corp | 3.05 | +1.60% |
| Acura Pharmaceuticals Inc | 2.36 | +0.85% |
Data is delayed by at least 15 min.